AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06411145
Drug: OXERVATE® 0.002%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenegermin-bkbj (20 mcg/mL) is an ophthalmic solution contained in a multiple-dose vial. The topical drops are administered 6 times/day for a 8-week course.
Trial: NCT06476899
Drug: FCR/BR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCR/BR
Trial: NCT05247216
Drug: Hemay007 800 mg QD group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily oral administrtion of Hemay007 800 mg QD for 12 weeks, 4 tablets of 200mg Hemay007 and 2 tablets of placebo.
Trial: NCT05247216
Drug: Hemay007 1200 mg QD group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily oral administrtion of Hemay007 1200 mg QD for 12 weeks, 6 tablets of 200mg Hemay007.
Trial: NCT05247216
Drug: Hemay007 600 mg QD group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily oral administrtion of Hemay007 600 mg QD for 12 weeks, 3 tablets of 200mg Hemay007 and 3 tablets of placebo.
Trial: NCT05247216
Drug: Hemay007 placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily oral administrtion of placebo for 12 weeks 6 tablets of placebo.
Trial: NCT04955327
Drug: A. Paniculata
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extract from A. Paniculata
Trial: NCT04955327
Drug: A. Chilensis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extract from A. Chilensis
Trial: NCT04955327
Drug: A. Paniculata and A. Chilensis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of A. Paniculata and A. Chilensis
Trial: NCT05614895
Drug: RO7223280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive RO7223280, 600 mg, IV infusion for 1 hour on Day 1.
Trial: NCT05614895
Drug: RO7223280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive RO7223280, 400 mg, IV infusion for 1 hour on Day 1.
Trial: NCT05293236
Drug: ApTOLL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ApTOLL is an aptamer (DNA single strain) designed to block TLR4 (toll-like receptor 4)
Trial: NCT04720742
Drug: Analytical Treatment Interruption + bNAbs infusion
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participant will perform an Analytical Treatment Interruption (ATI) of up to 18 months of duration. During the first 8 months, the participants will be infused once per month with a combination of the broadly neutralizing antibodies (bNAbs) 3BNC117 and 10-1074
Trial: NCT04835584
Drug: KRT-232
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.
Trial: NCT04498715
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZA), is a bisphosphonate, and has been shown to reduce the risk of hip fracture by 41% in post-menopausal women. For systemic injection, 4 mg (as per clinical protocol) will be injected intravenously 1-2 weeks after surgery. For local delivery, 1 or 2 mg Zoledronic Acid will be added to 5 or 10 mg CERAMENT BVF during mixing and the mixture will be injected.
Trial: NCT00002184
Drug: Levocarnitine
RxNorm normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05824338
Drug: General anesthesia for lumbar surgery
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will be intubated and ventilated under general anesthesia.
Trial: NCT05814640
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commonly used oral antipsychotics intervention therapy.
Trial: NCT06140966
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by vein: days 1-4 of each Induction cycle
Trial: NCT05203055
Drug: Nucleotide Analog
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etecavir 0.5mg qd or Tenofovir 300mg qd
Trial: NCT00043732
Drug: SCIO-469
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05572333
Drug: EP395
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule for oral use
Trial: NCT05572333
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule for oral use
Trial: NCT05394402
Drug: SHR0410 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR0410 Injection
Trial: NCT05394402
Drug: Placebo for SHR0410 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR0410 Injection blank preparation
Trial: NCT05226754
Drug: placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After enrolment, patients will be randomized (n=20 group A) to receive placebo capsules (lactose and magnesium stearate) every 12 hours for 10 days.
Trial: NCT05532254
Drug: Abilify® 10 mg tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an immediate-release tablet containing 10 mg Aripiprazole
Trial: NCT05068388
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05074498
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT05070104
Drug: modified FFX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan: 150mg/m2 IV over 90 min-14 day cycle Leucovorin: 400mg/m2 IV over 2hrs with Irinotecan-14 day cycle Oxaliplatin: 85mg/m2 IV over 2hrs-14 day cycle 5FU: 2400mg/m2 IV over 46-48 hrs-14 day cycle
Trial: NCT05000450
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy for lymphodepletion
Trial: NCT05646511
Drug: CAPOX
RxNorm normalized name: Capecitabine and Oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six cycles of CAPOX capecitabine 1000 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1, every 3 weeks
Trial: NCT05646511
Drug: CAPOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six cycles of CAPOXIRI capecitabine 800 mg/m2 orally twice daily on days 1-14, oxaliplatin 130 mg/m2 intravenously on day 1 and irinotecan 150 mg/m2 intravenously on day 1, every 3 weeks, if the initial dose of irinotecan 150 mg/m²/day is tolerated, the dose can be increased to 200 mg/m²/day from the second cycle
Trial: NCT05274984
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the control group will be given the same volume of saline.
Trial: NCT05062083
Drug: Ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen 75 mg orally once
Trial: NCT05062083
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: celecoxib 600 mg orally once
Trial: NCT05665088
Drug: BXCL501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual Film
Trial: NCT05665088
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual Placebo Film
Trial: NCT05424003
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution injected weekly for 72 weeks
Trial: NCT05406752
Drug: paracetamol Uniflash (125 mg/ 1.25 mL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oromucosal solution (125 mg/ 1.25 mL) for buccal route
Trial: NCT05077865
Drug: MYMD-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg capsule
Trial: NCT05077865
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching in appearance to MyMD-1 150mg capsule
Trial: NCT05373264
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A matching oral capsule containing placebo
Trial: NCT05173493
Drug: Tetracycline,Furazolidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline-Furazolidone-containing quadruple group
Trial: NCT05383456
Drug: HIV Anti-retroviral Background Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants are required be on continuous HIV Anti-retroviral Background Therapy.~No intervention on drug is part of the Study.
Trial: NCT04905316
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy will be as per standard of care in accordance with institutional practice. Patients will be treated with carboplatin or cisplatin with etoposide, paclitaxel, albumin-bound paclitaxel or pemetrexed at the discretion of the treating thoracic medical oncologist. Chemotherapy will be concurrent with radiation therapy as per standard practice, with cycle 1 day 1 of chemotherapy starting on fraction 1 of radiation ± 5 days.
Trial: NCT05324631
Drug: SHR0302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR0302, oral, once daily
Trial: NCT05324631
Drug: SHR0302 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR0302 placebo, oral, once daily
Trial: NCT05377619
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 1 hour before the challenge with intake of wine (200 ml) and a dinner
Trial: NCT05118698
Drug: Gynostemma
RxNorm normalized name: GYNOSTEMMA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the high-dose group and low-dose group will take gynostemma powder with a saponin content of 12% and 8% respectively, 3 times a day for 3 months.
Trial: NCT04780464
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 to 75 mg/m² intravenous, every 3 weeks for max 6 cycles until PD
Trial: NCT04780464
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 mg/m2 intravenous weekly for a maximum of 450 mg/m2 until PD
Trial: NCT04780464
Drug: Cyclophosphamide Oral Product
RxNorm normalized name: cyclophosphamide Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg BD on day 1 to day 7 of each 14 day cycle until PD
Trial: NCT04780464
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-20 mg on day 1 to day 7 of each 14 day cycle until PD
Trial: NCT05593627
Drug: Calcium Carbonate 500 MG Oral Tablet
RxNorm normalized name: Calcium Carbonate 500 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients undergoing heart valve surgery withcardiopulmonary bypass will take 500mg calcium carbonate
Trial: NCT03999840
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control drug for this study will be a placebo (sodium chloride 0.9% w/v for SC administration). Placebo will be prepared and labelled identically to cemdisiran.
Trial: NCT04860141
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the patient will take a pill that looks like gabapentin 2 hours prior to the procedure
Trial: NCT06447402
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL of normal saline will be nebulised in the control arm
Trial: NCT04660370
Drug: CKD-828, D097, D337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT04823520
Drug: TCA
RxNorm normalized name: RTCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive 6 sessions at 2 weeks intervals,the half face which will recieve MDA and TCA,MDA will be done before appling TCA.
Trial: NCT05296564
Drug: CYCLOPHOSPHAMIDE and FLUDARABIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. CYCLOPHOSPHAMIDE 250 mg/msq, Day -5,-4,-3 with FLUDARABIN 25 mg/msq, Day -5,-4,-3
Trial: NCT05296564
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CYCLOPHOSPHAMIDE 250 mg/msq, Day -6, -5,-4,-3
Trial: NCT04884399
Drug: CMAB818
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vascular endothelial growth factor (VEGF) inhibitor
Trial: NCT04884399
Drug: Lucentis®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vascular endothelial growth factor (VEGF) inhibitor
Trial: NCT06209359
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.
Trial: NCT05957848
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule taken daily
Trial: NCT05411367
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in each eye
Trial: NCT04808622
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo normal saline given as a one-time 7 mL one-time IV bolus injection
Trial: NCT05149365
Drug: Standard Prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard prophylaxis regimen for GVHD of Alternative Donor HSCT, include Cyclosporine (CsA),Methotrexate (MTX), Mycopherol ester (MMF) and Antithymic Globulin
Trial: NCT00104754
Drug: liposomal SN-38
RxNorm normalized name: sn-3-GPC
DrugBank: Choline alfoscerate (DB04660)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05889390
Drug: Cyclophosphamide/Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: according to the AC protocol
Trial: NCT06549309
Drug: JMKX003801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Ascending Single Dose of JMKX003801，Five（5）cohorts of 40 participants (each cohort contains 6 active and 2 placebo) are planned for evaluation.~For Ascending Multiple Dose of JMKX003801，Three（3）cohort of 30 participants (each cohort contains 8 active and 2 placebo) are planned for evaluation.
Trial: NCT06549309
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Ascending Single Dose of JMKX003801，Five（5）cohorts of 40 participants (each cohort contains 6 active and 2 placebo) are planned for evaluation.~For Ascending Multiple Dose of JMKX003801，Three（3）cohorts of 30 participants (each cohort contains 8 active and 2 placebo) are planned for evaluation.
Trial: NCT04531215
Drug: ultrasound guided Erector Spinae Plane
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ultrasound guided Erector Spinae Plane Block (ESPB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side.
Trial: NCT05502380
Drug: Standard antibiotic prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One to three intravenous doses of cefuroxime 1.5 g intravenously; or 3g if obesity; or vancomycin 1 g or clindamycin 600 mg; if allergy. Continuation of eventual current therapeutic antibiotc regimens for any infection
Trial: NCT04651361
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzyl benzoate and sesame oil served as placebo solution (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
Trial: NCT05297513
Drug: ActiveMatrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive weight based prophylactic antibiotics i.e. Ancef, vancomycin, or clindamycin. Drains will be used in fusion cases only. Intrawound vancomycin will be used for all instrumented cases.No negative pressure devices will be used. Anatomic layers will be closed in similar, standard fashion for all cases. For those randomized to the treatment group, the ActiveMatrix product will be administered on top of the dura mater and again on the closed fascia. Those in the control group, will forgo this step.
Trial: NCT04861376
Drug: Pueraria lobata
RxNorm normalized name: PUERARIA LOBATA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of Pueraria lobata granules is one sachet per day, 1.5g per sachet, which equivalent to 15g of the original drug.
Trial: NCT05520827
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00399230
Drug: Optive
RxNorm normalized name: optive
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03024177
Drug: Vapendavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vapendavir Tablets, 264 mg
Trial: NCT03024177
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vapendavir 264 mg matching tablets
Trial: NCT04874012
Drug: Active comparator Taurine
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive 3 g taurine, twice a day, as a powder for oral suspension (3 g/packet) for 12 weeks. Participants will be recommended to take the taurine immediately before the breakfast and dinner.
Trial: NCT05615532
Drug: LY3209590 (SC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT05615532
Drug: LY3209590 (IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV.
Trial: NCT05638893
Drug: Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (tablet/12hr) + celecoxib (200mg/day) for three months.
Trial: NCT05033808
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl is given once over 15 Minutes via a central line
Trial: NCT05505006
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anemic patients with folate deficiency will receive folic acid 5 mg per day for 1 month
Trial: NCT06629402
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive medication
Trial: NCT05926505
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is injected subcutaneously once daily for 4 weeks. After the period of 4 weeks, patients allocated to arm 1 will be shifted to subcutaneous treatment with 100mg anakinra once daily for 4 weeks.
Trial: NCT06629246
Drug: Conventional heart failure treatment
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional heart failure treatment, which may include pharmacological therapies such as diuretics, ACE inhibitors/ARBs, beta-blockers, or aldosterone receptor antagonists, based on the clinical requirements of the condition.
Trial: NCT04140279
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic solution, no active ingredient.
Trial: NCT06629246
Drug: Pogejiuxin decoction combined with conventional heart failure treatment
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In addition to receiving standard heart failure treatment, patients are also administered Pogejiuxin Decoction.The formula of Pogejiuxin Decoction is as follows : Processed Aconite 60g (decocted initially for 1 hour), Dried Ginger 60g, Honey-fried Licorice 60g, Cornus officinalis 60g, Ginseng 30g (decocted separately), Raw Dragon Bone 30g (decocted initially for 1 hour), Raw Oyster Shell 30g (decocted initially for 1 hour), Living Magnetite 30g, for a total of 7 prescriptions. Usage: Uniformly decocted with a herbal medicine decoction machine to obtain the medicinal liquid, one prescription per day, taken twice daily in the morning and evening, each time 100ml, for a continuous treatment of 7 days.
Trial: NCT05556356
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pre-operative acetaminophen (1000mg)
Trial: NCT00381147
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04872660
Drug: Gushen Antai Pill
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Gushen Antai Pill (GSATP, Z20030144) is composed of 10 herbs including radix-polygoni multiflori, radix rehmanniae praeparata, cistanche salsa, radix dipsaci, uncaria, semen cuscutae, rhizoma atractylodis macrocephalae, radix scutellariae, radix paeoniae lactiflorae. Its production follows GMP standards and takes the form of water honey pills, each bag of 6g.
Trial: NCT04872660
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo pill is produced by Beijing boran Pharmaceutical Co., Ltd. It can simulate the appearance, color and smell of GSATP formula, but it has no clinical effect because it has no active ingredients.
Trial: NCT05101616
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: albumin nanoparticle of paclitaxel 260 mg/m2、 ivdrip，d1，q3w； oxaliplatine 85mg/m2、ivdrip，d1，q3w； S-1 40 mg/m2，po, bid，d1\~d14，q3w. 3 cycles.
Trial: NCT04845178
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride, sterile, unpreserved, USP/PhEur
Trial: NCT05939466
Drug: Bedrocan®-type cannabis (22% THC, <1% CBD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decoction with 100 mg of Bedrocan®-type cannabis (22% THC, \<1% CBD)
Trial: NCT05678257
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT06576401
Drug: [14C] HDM1002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05893381
Drug: [177Lu]Lu-PSMA I&T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The radiopharmaceutical 177Lu-PSMA-I\&T will be administered, by slow intravenous injection, in 2 cycles of treatment at 6-8 weekly intervals at a dosage of 7.4 GBq.